Dear colleagues,

With great pleasure, I invite you to join us at this Teva-sponsored satellite symposium, taking place during the virtual 6th Congress of the European Academy of Neurology (EAN).

In recent years, an ongoing evolution in the migraine prevention landscape has been a cause for optimism in our quest to improve the lives of our patients. A deepening understanding of migraine pathophysiology has identified novel targets for preventive therapy and several anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies are now approved in Europe. As data continue to emerge – from clinical trials and the real world – we are accumulating insights that inform the optimal use of these antibodies in clinical practice.

During this virtual symposium, we will review the considerable burden of migraine from a patient perspective and discuss what insights for targeted prevention can be gained from the latest research on the neurovascular pathophysiology of migraine. We will also explore the latest data on anti-CGRP monoclonal antibodies, including from patients with comorbidities and difficult-to-treat migraine, and discuss their impact on clinical decision-making.

I hope you will join us for what promises to be an engaging and informative symposium.

Messoud Ashina, Chair
Rigshospitalet Glostrup and University of Copenhagen
Copenhagen, Denmark